Optimization of Mutation Detection by the Fully-automated QPCR-based Idylla System on Tumor Tissue from Patients with Non-small Cell Lung Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 22

PMID 29262544

Citations 20

Authors

Marius Ilie

Catherine Butori

Sandra Lassalle

Simon Heeke

Nicolas Piton

Jean-Christophe Sabourin

Virginie Tanga

Kevin Washetine

Elodie Long-Mira

Priscilla Maitre

Nathalie Yazbeck

Olivier Bordone

Virginie Lespinet

Sylvie Leroy

Charlotte Cohen

Jerome Mouroux

Charles Hugo Marquette

Veronique Hofman

Paul Hofman

Affiliations

Soon will be listed here.

Abstract

Treatment with EGFR inhibitors is limited to patients with advanced/metastatic non-small cell lung cancer who have known mutations. Currently, patient care has to respond to several imperatives to make these inhibitors broadly available to all patients; fast and accurate detection of mutations by a sensitive and specific standardized cost-effective method, easy-to-implement in settings with limited expertise in molecular diagnostics. We evaluated the Idylla™ EGFR Mutation Assay (Biocartis) for the detection of mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples from a series of 55 patients with lung adenocarcinoma and compared these results with those obtained by a pyrosequencing ISO-15189 accredited laboratory method. The comparison was made on both whole surgical tumor sections and on three artificially constructed small biopsies (∼1 mm) from the same FFPE blocks. Cost-effectiveness and turnaround time comparison between the two methods was performed. On both whole tissue sections and on biopsy cores, the Idylla™ and pyrosequencing had an agreement of 95% (52/55). The Idylla™ Assay produced results faster and more cost-effective than pyrosequencing. The Idylla™ system showed a good sensitivity and was cost-saving in our setting. Because of the easy workflow, the Idylla™ system has the potential to expand EGFR testing to more pathology laboratories in a reliable and fast manner.

Citing Articles

High Incidence of False Positives in S768I Mutation Detection Using the Idylla qPCR System in Non-Small Cell Lung Cancer Patients.

Carnero-Gregorio M, Perera-Gordo E, de-la-Pena-Castro V, Gonzalez-Martin J, Delgado-Sanchez J, Rodriguez-Cerdeira C Diagnostics (Basel). 2025; 15(3).

PMID: 39941251 PMC: 11816987. DOI: 10.3390/diagnostics15030321.

The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.

Roy-Chowdhuri S, Mani H, Fox A, Tsao A, Sholl L, Farjah F Cancer. 2024; 130(24):4200-4212.

PMID: 39347608 PMC: 11585344. DOI: 10.1002/cncr.34926.

Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.

Joshi P, Gogte P, Pai T, Gurav M, Dhanawade D, Karnik N Int J Exp Pathol. 2024; 105(3):90-99.

PMID: 38717047 PMC: 11129959. DOI: 10.1111/iep.12503.

Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR.

Leonce C, Guerriau C, Chalabreysse L, Duruisseaux M, Couraud S, Brevet M Int J Mol Sci. 2023; 24(21).

PMID: 37958668 PMC: 10648419. DOI: 10.3390/ijms242115684.

Advanced Non-small Cell Lung Cancer: EGFR Mutation Analysis Using Pyrosequencing and the Fully Automated qPCR-Based Idylla System.

Boustany Y, Laraqui A, El Zaitouni S, Ghaouti M, Benzekri A, Kettani F Cancer Control. 2023; 30:10732748231177538.

PMID: 37196225 PMC: 10196548. DOI: 10.1177/10732748231177538.

References

Andre F, Nowak F, Arnedos M, Lacroix L, Viens P, Calvo F . Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res. 2012; 18(6):1555-60. DOI: 10.1158/1078-0432.CCR-11-2201. View

Fenizia F, De Luca A, Pasquale R, Sacco A, Forgione L, Lambiase M . EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol. 2015; 11(11):1611-23. DOI: 10.2217/fon.15.23. View

Devarakonda S, Morgensztern D, Govindan R . Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015; 16(7):e342-51. DOI: 10.1016/S1470-2045(15)00077-7. View

Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragon E . Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Exp Mol Pathol. 2015; 99(3):485-91. DOI: 10.1016/j.yexmp.2015.09.004. View

Sheikine Y, Rangachari D, McDonald D, Huberman M, Folch E, VanderLaan P . EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016; 17(6):483-492. DOI: 10.1016/j.cllc.2016.05.016. View

Lim C, Tsao M, Le L, Shepherd F, Feld R, Burkes R . Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015; 26(7):1415-21. DOI: 10.1093/annonc/mdv208. View

Janku F, Claes B, Huang H, Falchook G, Devogelaere B, Kockx M . BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015; 6(29):26886-94. PMC: 4694960. DOI: 10.18632/oncotarget.4723. View

Sahnane N, Gueli R, Tibiletti M, Bernasconi B, Stefanoli M, Franzi F . Pyrosequencing for EGFR mutation detection: diagnostic accuracy and clinical implications. Diagn Mol Pathol. 2013; 22(4):196-203. DOI: 10.1097/PDM.0b013e3182893f55. View

Yeo M, Jung M, Lee S, Lee Y, Hur G, Kim J . The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. J Clin Pathol. 2016; 70(3):260-265. DOI: 10.1136/jclinpath-2016-204025. View

10.

Tan D, Yom S, Tsao M, Pass H, Kelly K, Peled N . The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016; 11(7):946-63. DOI: 10.1016/j.jtho.2016.05.008. View

11.

Sholl L, Aisner D, Allen T, Beasley M, Borczuk A, Cagle P . Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med. 2016; 140(4):341-4. DOI: 10.5858/arpa.2015-0506-SA. View

12.

Zhang Y, Yuan J, Wang K, Fu X, Han X, Threapleton D . The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7(48):78985-78993. PMC: 5346692. DOI: 10.18632/oncotarget.12587. View

13.

Minguet J, Smith K, Bramlage P . Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. Int J Cancer. 2015; 138(11):2549-61. DOI: 10.1002/ijc.29915. View

14.

Hiley C, Le Quesne J, Santis G, Sharpe R, Gonzalez de Castro D, Middleton G . Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016; 388(10048):1002-11. DOI: 10.1016/S0140-6736(16)31340-X. View

15.

Deeb K, Hohman C, Risch N, Metzger D, Starostik P . Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing. Arch Pathol Lab Med. 2015; 139(7):913-21. DOI: 10.5858/arpa.2014-0095-OA. View

16.

Lindeman N, Cagle P, Beasley M, Chitale D, Dacic S, Giaccone G . Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular.... J Mol Diagn. 2013; 15(4):415-53. DOI: 10.1016/j.jmoldx.2013.03.001. View

17.

Young E, Owens M, Adebiyi I, Bedenham T, Butler R, Callaway J . A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol. 2013; 22(4):190-5. DOI: 10.1097/PDM.0b013e318294936c. View

18.

Tan W, Jain A, Takano A, Newell E, Iyer N, Lim W . Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016; 17(8):e347-e362. DOI: 10.1016/S1470-2045(16)30123-1. View

19.

Hofman P, Popper H . Pathologists and liquid biopsies: to be or not to be?. Virchows Arch. 2016; 469(6):601-609. DOI: 10.1007/s00428-016-2004-z. View

20.

Ilie M, Hofman V, Dietel M, Soria J, Hofman P . Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016; 468(5):511-25. DOI: 10.1007/s00428-016-1910-4. View